Vertex Pharmaceuticals Incorporated (VRTX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Vertex Pharmaceuticals Incorporated (VRTX) is Neutral.

The composite score behind that read is +0.15, weighing +0.16 of bullish evidence against -0.21 bearish.

Vertex Pharmaceuticals Incorporated last closed at $510.08, +1.36% on the session.

Against the IVW growth benchmark the position is +0.56% over the forecast window.

The read is built from 15 underlying insights — 10 bullish and 5 bearish.

Agreement across those insights is 67%.

5 graded predictions for VRTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Vertex Pharmaceuticals Incorporated in the 30th percentile on valuation and the 83rd percentile on return on equity, where 100 is best.

Vertex Pharmaceuticals Incorporated is classified under Health Care / Biotechnology, with a market capitalisation of $127.55B.

StockMap tracks Vertex Pharmaceuticals Incorporated as the 4th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Vertex Pharmaceuticals Incorporated ranks 30th of 381 in the group, against a group median of -0.08.